FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2069324192> ?p ?o ?g. }

• W2069324192 endingPage "413" @default.
• W2069324192 startingPage "405" @default.
• W2069324192 abstract "Dysregulation of the neuronal nicotinic acetylcholine receptor (NNR) system has been implicated in attention-deficit/hyperactivity disorder (ADHD), and nicotinic agonists improve attention across preclinical species and humans. Hence, a randomized, double-blind, placebo-controlled, crossover study was designed to determine the safety and efficacy of a novel α4β2 NNR agonist (ABT-894 (3-(5,6-dichloro-pyridin-3-yl)-1(S),5 (S)-3,6-diazabicyclo[3.2.0]heptane)) in adults with ADHD. Participants (N=243) were randomized to one of four dose regimens of ABT-894 (1, 2, and 4 mg once daily (QD)) or 4 mg twice daily (BID) or the active comparator atomoxetine (40 mg BID) vs placebo for 28 days. Following a 2-week washout period, participants crossed over to the alternative treatment condition (active or placebo) for an additional 28 days. Primary efficacy was based on an investigator-rated Conners’ Adult ADHD Rating Scale (CAARS:Inv) Total score at the end of each 4-week treatment period. Additional secondary outcome measures were assessed. A total of 238 patients were assessed for safety end points, 236 patients were included in the intent-to-treat data set, and 196 were included in the completers data set, which was the prespecified, primary data set for efficacy. Both the 4 mg BID ABT-894 and atomoxetine groups demonstrated significant improvement on the primary outcome compared with placebo. Several secondary outcome measures were also significantly improved with 4 mg BID ABT-894. Overall, ABT-894 was well tolerated at all dose levels. These results provide initial proof of concept for the use of α4β2 agonists in the treatment of adults with ADHD. Further investigation of ABT-894, including higher doses, is therefore warranted." @default.
• W2069324192 created "2016-06-24" @default.
• W2069324192 creator A5006661051 @default.
• W2069324192 creator A5007169910 @default.
• W2069324192 creator A5030348867 @default.
• W2069324192 creator A5034426466 @default.
• W2069324192 creator A5034584090 @default.
• W2069324192 creator A5041808631 @default.
• W2069324192 creator A5067332869 @default.
• W2069324192 creator A5087369453 @default.
• W2069324192 date "2012-10-03" @default.
• W2069324192 modified "2023-10-09" @default.
• W2069324192 title "A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of α4β2 Agonist ABT-894 in Adults with ADHD" @default.
• W2069324192 cites W1603286332 @default.
• W2069324192 cites W1853960255 @default.
• W2069324192 cites W1970966565 @default.
• W2069324192 cites W1979919601 @default.
• W2069324192 cites W1991926863 @default.
• W2069324192 cites W2002997534 @default.
• W2069324192 cites W2006852753 @default.
• W2069324192 cites W2008409978 @default.
• W2069324192 cites W2010073589 @default.
• W2069324192 cites W2016366678 @default.
• W2069324192 cites W2023647188 @default.
• W2069324192 cites W2026549843 @default.
• W2069324192 cites W2032557741 @default.
• W2069324192 cites W2044210997 @default.
• W2069324192 cites W2044831514 @default.
• W2069324192 cites W2048439122 @default.
• W2069324192 cites W2048740041 @default.
• W2069324192 cites W2053295943 @default.
• W2069324192 cites W2054364733 @default.
• W2069324192 cites W2055671737 @default.
• W2069324192 cites W2057196462 @default.
• W2069324192 cites W2059361491 @default.
• W2069324192 cites W2059495695 @default.
• W2069324192 cites W2073345301 @default.
• W2069324192 cites W2077454035 @default.
• W2069324192 cites W2078945716 @default.
• W2069324192 cites W2082418672 @default.
• W2069324192 cites W2085316111 @default.
• W2069324192 cites W2088566077 @default.
• W2069324192 cites W2091621243 @default.
• W2069324192 cites W2109356111 @default.
• W2069324192 cites W2114290463 @default.
• W2069324192 cites W2114300613 @default.
• W2069324192 cites W2122411644 @default.
• W2069324192 cites W2129098849 @default.
• W2069324192 cites W2139053364 @default.
• W2069324192 cites W2145890268 @default.
• W2069324192 cites W2167062019 @default.
• W2069324192 cites W4236486344 @default.
• W2069324192 doi "https://doi.org/10.1038/npp.2012.194" @default.
• W2069324192 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3547191" @default.
• W2069324192 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23032073" @default.
• W2069324192 hasPublicationYear "2012" @default.
• W2069324192 type Work @default.
• W2069324192 sameAs 2069324192 @default.
• W2069324192 citedByCount "48" @default.
• W2069324192 countsByYear W20693241922012 @default.
• W2069324192 countsByYear W20693241922013 @default.
• W2069324192 countsByYear W20693241922014 @default.
• W2069324192 countsByYear W20693241922015 @default.
• W2069324192 countsByYear W20693241922016 @default.
• W2069324192 countsByYear W20693241922017 @default.
• W2069324192 countsByYear W20693241922018 @default.
• W2069324192 countsByYear W20693241922019 @default.
• W2069324192 countsByYear W20693241922020 @default.
• W2069324192 countsByYear W20693241922021 @default.
• W2069324192 countsByYear W20693241922022 @default.
• W2069324192 countsByYear W20693241922023 @default.
• W2069324192 crossrefType "journal-article" @default.
• W2069324192 hasAuthorship W2069324192A5006661051 @default.
• W2069324192 hasAuthorship W2069324192A5007169910 @default.
• W2069324192 hasAuthorship W2069324192A5030348867 @default.
• W2069324192 hasAuthorship W2069324192A5034426466 @default.
• W2069324192 hasAuthorship W2069324192A5034584090 @default.
• W2069324192 hasAuthorship W2069324192A5041808631 @default.
• W2069324192 hasAuthorship W2069324192A5067332869 @default.
• W2069324192 hasAuthorship W2069324192A5087369453 @default.
• W2069324192 hasBestOaLocation W20693241921 @default.
• W2069324192 hasConcept C118552586 @default.
• W2069324192 hasConcept C126322002 @default.
• W2069324192 hasConcept C142724271 @default.
• W2069324192 hasConcept C15744967 @default.
• W2069324192 hasConcept C168563851 @default.
• W2069324192 hasConcept C170493617 @default.
• W2069324192 hasConcept C197934379 @default.
• W2069324192 hasConcept C204787440 @default.
• W2069324192 hasConcept C27081682 @default.
• W2069324192 hasConcept C2777112843 @default.
• W2069324192 hasConcept C2778781522 @default.
• W2069324192 hasConcept C2778938600 @default.
• W2069324192 hasConcept C2780783007 @default.
• W2069324192 hasConcept C42219234 @default.
• W2069324192 hasConcept C71924100 @default.
• W2069324192 hasConcept C87813604 @default.
• W2069324192 hasConcept C98274493 @default.

• next